TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04244318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-feedback ODISEA 3.0
Description: Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-feedback ODISEA 3.0
Description: Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ODISEA-DTP: parental therapy
Description: Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ODISEA-DTP: parental therapy
Description: Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia
Study: NCT06253130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP1734
Description: PARP1 selective inhibitor
Study: NCT05891977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A - Tomato paste
Description: Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A - Tomato paste
Description: Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention B - Control
Description: Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention B - Control
Description: Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
Study: NCT05528380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA + Fitbit Intervention
Description: Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
Study: NCT06306365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern board game-based learning
Description: Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
Study: NCT04732039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of peak oxygen uptake
Description: Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of peak oxygen uptake
Description: Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
Study: NCT04888585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT04927975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT04927975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT06107517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DREAMS-OT
Description: Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach.
Study: NCT05123638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality cycling exercise
Description: Daily voluntary cycling for up to 30 minutes with the virtual reality technology
Study: NCT04922216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Standard)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Standard)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Standard)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
Study: NCT06357858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INQOVI (decitabine and cedazuridine)
Description: Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered on D8 with every 4 week cycle.
Study: NCT06441669

Intervention type: DRUG
Intervention: Letermovir
Description: Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Study: NCT05123638

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised stationary cycling exercise
Description: Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
Study: NCT06029738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)
Description: MCT-OCD is a group education for OCD patients.
Study: NCT04922216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Adaptive)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Adaptive)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
Study: NCT05251285

Intervention type: PROCEDURE
Intervention: Nipple-Sparing Mastectomy
Description: Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
Study: NCT04922216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Adaptive)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
Study: NCT06533917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Main Group
Description: Thoracolumbar spine AP, Thoracolumbar spine LAT
Study: NCT05247593

Intervention type: DRUG
Intervention: Dayingpian
Description: The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.

Intervention type: DRUG
Intervention: Dayingpian
Description: The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.

Intervention type: DRUG
Intervention: conventional mood stabilizers
Description: Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.

Intervention type: DRUG
Intervention: conventional mood stabilizers
Description: Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
Study: NCT04922216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
Study: NCT06167564

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine allergy tests
Description: Prick test, specific IgE detection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Newly developed microarray-based diagnostic test system
Description: Newly developed microarray-based diagnostic test system for the detection of the specific IgE
Study: NCT04922216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
Study: NCT05650866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activation of pro-erectile nerves within the pelvic plexus
Description: The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
Study: NCT06221449

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positive end expiratory pressure
Description: The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end expiratory pressure
Description: The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end expiratory pressure
Description: The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O.
Study: NCT05712395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
Study: NCT06545617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT8006 for Injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT8006 for Injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT8006 for Injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
Study: NCT06681766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomlabofusp
Description: Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.